Effects of antiparkinsonian drugs on muscarinic receptor binding in rat brain, heart and lungSYVALAHTI, E. K. G; KUNELIUS, R; LAUREN, L et al.Pharmacology & toxicology. 1988, Vol 62, Num 2, pp 90-94, issn 0901-9928Article

Differences in cardiac but not in neuroendocrine responses in healthy volunteers after administration of two antimuscarinic agents, atropine and pirenzepineSYVALAHTI, E. K. G; YLITALO, A.Life sciences (1973). 1986, Vol 39, Num 9, pp 843-850, issn 0024-3205Article

Citalopram in patients with unsatisfactory response to neuroleptics : an open follow-up studySYVÄLAHTI, E. K. G; KALLIONIEMI, H; LEHTO, H et al.Methods and findings in experimental and clinical pharmacology. 1994, Vol 16, Num 1, pp 49-55, issn 0379-0355Article

Metabolism of nomifensine after oral and intravenous administrationLINDBERG, R. L. P; SYVÄLAHTI, E. K. G.Clinical pharmacology and therapeutics. 1986, Vol 39, Num 4, pp 378-383, issn 0009-9236Article

Interaction of psychotropic drugs with brain muscarinic cholinoceptors: similarities of biperiden with pirenzepine in receptor binding propertiesSYVALAHTI, E. K. G; LAUREN, L; MARKKANEN, J et al.Acta pharmacologica et toxicologica. 1987, Vol 60, Num 1, pp 66-69, issn 0001-6683Article

Inhibitory effects of neuroleptics on debrisoquine oxidation in manSYVALAHTI, E. K. G; LINDBERG, R; KALLIO, J et al.British journal of clinical pharmacology. 1986, Vol 22, Num 1, pp 89-92, issn 0306-5251Article

The dopamine D₂ receptor 5'-flanking variant, ^-141C Ins/Del, is not associated with reduced dopamine D₂ receptor density in vivoPOHJALAINEN, T; NAGREN, K; SYVÄLAHTI, E. K. G et al.Pharmacogenetics (London). 1999, Vol 9, Num 4, pp 505-509, issn 0960-314XArticle

Comparison of the effects of metochlopramide on sympathetic and muscarinic responses after pretreatment with atropine and pirenzepineSYVALAHTI, E. K. G; YLITALO, A; SCHEININ, M et al.International journal of clinical pharmacology, therapy and toxicology (1980). 1988, Vol 26, Num 1, pp 16-21, issn 0174-4879Article

Effects of intravenous and subcutaneous administration of apomorphine on the clinical symptoms of chronic schizophrenicsSYVALAHTI, E. K. G; SAKO, E; SCHEININ, M et al.British journal of psychiatry (Print). 1986, Vol 148, Num 2, pp 204-208, issn 0007-1250Article

Effects of apomorphine on blood levels of homovanillic acid, growth hormone and prolactin in medicated schizophrenics and healthy control subjectsSCHEININ, M; SYVALAHTI, E. K. G; HIETALA, J et al.Progress in neuro-psychopharmacology & biological psychiatry. 1985, Vol 9, Num 4, pp 441-449, issn 0278-5846Article